SecBot SecBot

ARMP drug pipeline

$2.99
−22.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±8.4%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2 complete; Phase 3 (registrational) planned for H2 2026
Time to marketPhase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.

AP-SA02 Updated Aug 20

What to watch

Watch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.

Bull case
  • Phase 2 completed with results posted, and Armata has submitted the Phase 3 superiority protocol to the FDA with all End-of-Phase 2 meeting comments addressed; the Phase 3 study is on track to initiate in H2 2026 (SEC 8-K, Jul 20, 2026).
  • FDA agreement on the initial pediatric study plan for AP-SA02 in complicated S. aureus bacteremia, a regulatory milestone on the path toward a future BLA (PRNewswire, Jul 13, 2026).
  • Non-dilutive government support: a $2.5M DoD award continuation brings total funding under the award to $28.7M (SEC 8-K, Jul 20, 2026).
Bear case
  • Pre-revenue and cash-constrained: Q1 2026 net loss of $115.3M (largely non-cash fair-value charges) with only ~$4.8M cash before the Innoviva loan; the company will likely need more (potentially dilutive) capital to complete a Phase 3 (SEC 8-K/10-Q, May 13, 2026).
  • No near-term binary: Phase 3 initiation in H2 2026 means pivotal topline data is likely 2+ years away, with high clinical failure risk and no PDUFA scheduled within ~12 months.
  • Phage therapy is a novel, thinly precedented regulatory and commercial path, manufacturing scale-up (four engineering runs done, clinical trial material still next) and FDA acceptance remain open risks.
● neutral
Impact
PhasePhase 2 (completed)
Time to marketAP-PA02 is in the post-Phase 2 stage with no announced pivotal/Phase 3 trial start. If a Phase 3 program were initiated, a commercial launch would likely be several years away.

AP-PA02 Updated Nov 15

What to watch

Monitor Armata's subsequent quarterly updates for any signal that AP-PA02's development is being revived (e.g., a Phase 3 plan, partnership, or non-dilutive funding). For now, ARMP's value thesis depends almost entirely on the AP-SA02 Phase 3 program, not on AP-PA02.

Bull case
  • AP-PA02 demonstrated positive Phase 2 data across two distinct patient populations (CF and NCFB), showing durable bacterial reduction and a favorable safety profile, which could support registration if further developed.
  • Patents issued in October 2026 protect AP-PA02 through at least 2041, providing long-term intellectual property protection.
  • The drug targets a large unmet need: chronic Pseudomonas aeruginosa lung infections in patients with limited antibiotic options, and phage therapy could complement or replace standard-of-care antibiotics as antimicrobial resistance grows.
Bear case
  • AP-PA02 has no announced path to a pivotal trial; company resources and management focus are directed almost entirely at the lead candidate AP-SA02, which has Breakthrough Therapy designation and is moving toward Phase 3.
  • With no upcoming binary catalyst (phase 3 start, readout, or regulatory decision) on the visible horizon, AP-PA02 is unlikely to be a near-term driver of ARMP's share price.
  • The stock is down 74% from its 52-week high of $14.98, trading at $3.87, reflecting both the market's focus on AP-SA02's binary Phase 3 risk and the company's operating cash burn.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
May 7, 2026AP-SA02Fast Track−8.4%−9.5%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
AP-SA02Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus BacteremiaPhase 2Completed · results56Nov 7, 2024